CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY CONSULTING AGREEMENTConsulting Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Pennsylvania
THIS CONSULTING AGREEMENT (“Agreement”) is made and entered into on February 25, 2021 by and between Evan G. Dick, PhD (“Consultant”), and Context Therapeutics LLC, a Delaware limited liability company (“Company”).
VOTING AGREEMENTVoting Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT (this “Agreement”), is made and entered into as of this 22nd day of December, 2020, by and among Context Therapeutics LLC, a Delaware limited liability company (the “Company”), each holder of the Series A Preferred Units of the Company (“Series A Units”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsections 6.1(a) or 6.2 below, the “Investors”), each holder of Series Seed Units of the Company (“Series Seed Units” and, collectively with the Series A Units, the “Preferred Units”) listed on Schedule B hereto and any other unitholders of the Company or transferees who become parties hereto (collectively with the Investors, the “Unitholders”).
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Delaware
THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 22nd day of December, 2020 by and among Context Therapeutics LLC, a Delaware limited liability company (the “Company”) and the Investors (as defined below) listed on Schedule A.
RESEARCH COLLABORATION AND LICENSE AGREEMENT FOR CLAUDIN 6 BISPECIFIC ANTIBODIES BY AND BETWEEN CONTEXT THERAPEUTICS, LLC and INTEGRAL MOLECULAR, INC. APRIL 6, 2021 Certain identified information has been omitted from this exhibit because it is not...Research Collaboration and License Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Pennsylvania
This Research Collaboration and License Agreement (the “Agreement”) is entered into and effective as of April 6, 2021 (the “Effective Date”), by and between Integral Molecular, Inc., a Delaware corporation (“Integral”), having its principal place of business at 3711 Market St. Suite 900, Philadelphia, PA 19104, and Context Therapeutics, LLC, a company organized under the laws of Delaware (“Context”), having its principal place of business at 3675 Market Street, Suite 200, Philadelphia, PA 19104, USA.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of December 15, 2017 (the “Agreement Date”), is entered into by and between Context Biopharma Inc., a Delaware corporation (“Buyer”), and ARNO THERAPEUTICS, INC., a Delaware corporation (“Seller”). Buyer and Seller are referred to collectively herein as the “Parties” and each as a “Party.”
BOARD OF DIRECTOR SERVICES AGREEMENTBoard of Director Services Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Delaware
This BOARD OF DIRECTOR SERVICES AGREEMENT (the “Agreement”) is made and entered into effective as of this 5th day of March 2021 (the “Effective Date”), by and between Context Therapeutics LLC, a Delaware limited liability company, which is expected to be converted to a Delaware corporation pursuant to a statutory conversion and change its name to Context Therapeutics Inc. (together, the “Company”), and (“Director”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 3rd, 2021 • Context Therapeutics LLC • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 22nd day of December, 2020, by and among Context Therapeutics LLC, a Delaware limited liability company (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 4.9 hereof.
